Trial · NCT07896642
Brown Adipose Tissue Modulation in Polycystic Ovary Syndrome Using Infrared Thermography
NCT07896642, Not applicable, Recruiting, Istanbul Health and Technology University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Brown Adipose Tissue Modulation in Polycystic Ovary Syndrome Using Infrared Thermography. Trials, record NCT07896642. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07896642
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Brown Adipose Tissue Modulation in Polycystic Ovary Syndrome Using Infrared Thermography
- NCT number
- NCT07896642
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Istanbul Health and Technology University
- Conditions
- Polycystic Ovary Syndrome (PCOS)
- Interventions
- inositol
- First posted
- 2026-10-27
- Last updated
- 2026-11-12
Source ClinicalTrials.gov
Registered outcomes26
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Supraclavicular Skin Temperature (Tscv) | At baseline for all participants | Supraclavicular skin temperature (Tscv) will be measured with a FLIR E5 Pro infrared thermal imaging camera after a standardized mild cold exposure protocol (hand immersion in cold water for 5 minutes). Mean temperatures of the right and left supraclavicular regions of interest will be averaged to obtain a single Tscv value, reported in degrees Celsius (°C), as an indicator of brown adipose tissue activity. |
| Primary | Serum Uncoupling Protein 1 (UCP-1) Level | At baseline for all participants | Serum UCP-1 concentration will be measured using a commercial human sandwich ELISA kit as a biochemical marker of brown adipose tissue activity and thermogenesis, and reported in ng/L. |
| Secondary | Relative Supraclavicular Skin Temperature (Trel) | At baseline for all participants | Relative supraclavicular skin temperature (Trel) will be calculated as the difference between Tscv and the reference skin temperature (Tref) measured over the sternal region (corpus sterni), a region without brown adipose tissue, on the same thermal image (Trel = Tscv - Tref). Values from the right and left sides will be averaged to obtain a single Trel value, reported in degrees Celsius (°C). |
| Secondary | Body Temperature | At baseline for all participants | Body temperature will be measured and reported in degrees Celsius (°C). |
| Secondary | Body Weight | At baseline for all participants | Body weight will be measured and reported in kilograms (kg). |
| Secondary | Waist Circumference | At baseline for all participants | Waist circumference will be measured and reported in centimeters (cm). |
| Secondary | Body Mass Index (BMI) | At baseline for all participants | BMI will be calculated as body weight in kilograms divided by the square of height in meters and reported in kg/m². |
| Secondary | Body Fat Percentage | At baseline for all participants | Body fat percentage will be measured using a household-type Tanita body composition scale (bioelectrical impedance) and reported as a percentage (%) of total body weight. |
| Secondary | Basal Metabolic Rate | At baseline for all participants | Basal metabolic rate will be estimated using a household-type Tanita body composition scale (bioelectrical impedance) and reported in kilocalories per day (kcal/day). |
| Secondary | Systolic Blood Pressure | At baseline for all participants | Systolic blood pressure will be measured and reported in millimeters of mercury (mmHg). |
1 to 10 of 26Source ClinicalTrials.gov
See all 26 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07896642
GET https://conductscience.org/api/trials/v1/NCT07896642/registered?page=2